Standard BioTools (LAB) Q4 2025 earnings review
A $550M War Chest Masks Core Operational Contraction
Standard BioTools enters 2026 as a completely different company following the divestiture of SomaLogic, armed with ~$550 million in cash to pursue M&A. Management praised a 'strong finish' to 2025, but the financials tell a sobering story. The headline Q4 net income of $13.9 million is an accounting mirage driven entirely by a one-time $38.4 million tax valuation allowance release. Core operations remain deeply unprofitable, with a Q4 operating loss of $24.6 million. Even more concerning: FY26 guidance projects continuing operations revenue to contract again, making it clear that growth will have to be bought rather than organically generated.
🐂 Bull Case
The SomaLogic divestiture to Illumina closed in January 2026, injecting ~$550 million in cash. Combined with ~$1 billion in NOL carryforwards, LAB is heavily capitalized to execute its strategy of disciplined consolidation in the life sciences sector.
The company fully operationalized over $40 million in annualized savings. Full-year non-GAAP operating expenses dropped 4% to $108.3M, paving a legitimate, albeit slow, path toward their target of positive adjusted EBITDA exiting 2026.
🐻 Bear Case
Consumables, the high-margin recurring engine of the business, fell a staggering 17% YoY in Q4 to $9.0 million, accelerating from an 11% decline for the full year.
FY26 revenue guidance of $80-$85 million implies a contraction from FY25's $85.3 million. The organic core business is failing to find a bottom amidst macro funding pressures.
⚖️ Verdict: 🔴
Bearish on organic operations, Neutral on the stock. The base business is shrinking and bleeding cash. However, valuing the company now is less about its current products and more about how management deploys its massive $550M cash pile. Until accretive M&A is announced, the core business fundamentals are weak.
Key Themes
The Net Income Mirage
Management's claim of a 'strong finish' is sharply contradicted by the income statement. The company reported a Q4 net income of $13.9 million (reversing from a $27.2M loss last year). However, this was entirely driven by a $35.9 million net tax benefit, primarily a one-time, non-cash $38.4 million release of a deferred tax valuation allowance tied to the divestitures. Excluding this accounting maneuver, the operating loss was $24.6 million. Operations are not profitable.
Consumables Drag Intensifies
The highest quality revenue stream is deteriorating. Consumables revenue decelerated sharply, falling 17% YoY in Q4 to $9.0 million (compared to -11% for the full year). Management cited project funding declines in flow and microfluidics. A shrinking consumables base means the installed instrument base is underutilized, which pressures long-term margin expansion.
Instrument Sales Reversing the Trend
In a bright spot for the quarter, Instruments revenue grew 10% YoY to $8.5 million, a significant reversal from the 26% YoY decline reported back in Q2. Management noted strong growth in imaging (historically driven by the Hyperion XTi platform), though they cautioned that broader capital-constrained end-markets, particularly in the Americas, remain a macroeconomic headwind.
M&A War Chest Secured
The sale of SomaLogic to Illumina successfully closed in January 2026. This shifts LAB's identity from an operator of struggling legacy assets to a holding company with ~$550 million in cash and ~$1 billion in Net Operating Losses (NOLs). This massive liquidity pool is the company's primary growth driver moving forward, enabling them to acquire distressed or undervalued life science assets.
Standard BioTools Business System (SBS) Delivering Slower Burn
Cost discipline is holding up. Non-GAAP operating expenses for FY25 fell 4% to $108.3 million. Q4 operating expenses were down 4% YoY even including $2.1M in restructuring charges. The company has fully operationalized its targeted $40 million in savings, keeping the adjusted EBITDA loss roughly flat YoY (-$15.8M in Q4) despite lower revenues.
Other KPIs
Stable. Only a slight 3% improvement from a -$64.2 million loss in FY24. While management points to a path to positive adjusted EBITDA exiting 2026, closing a $60M+ annualized gap will require significant operational leverage, which is hard to achieve with declining revenues.
Accelerating from 48.1% in 24Q4. The 220 basis point improvement was driven by favorable volume in higher-margin instrument sales and product mix, showing that when the company does secure sales, unit economics are slowly improving.
Stable, up 1% YoY. Increased demand from pharmaceutical customers for Lab Services offset lower Field Services revenue. Notably, the drop in Field Services was partially attributed to 'improved instrument quality and uptime,' which is a positive long-term operational signal despite the short-term revenue hit.
Guidance
Decelerating. The midpoint of $82.5 million represents a 3.3% decline from FY25's $85.3 million. Given the massive restructuring and focus on the base business, guiding for another year of contraction indicates management expects ongoing macro headwinds (NIH funding pressures) to outweigh organic commercial initiatives.
Key Questions
M&A Deployment Timeline
With ~$550 million now secured from the SomaLogic sale, what is the expected timeline and target profile for deploying this capital? Are you prioritizing scale, immediate EBITDA accretion, or technological synergies?
Consumables Trajectory
Consumables fell 17% in Q4. How much of this is driven by temporary NIH funding constraints versus permanent loss of market share or lower utilization of the installed instrument base?
Path to EBITDA Breakeven
You reiterated the goal of exiting 2026 with positive adjusted cash flow and EBITDA. Given FY26 revenue is guided down to $80-$85M, will this profitability target be achieved solely through further cost cuts, or does it rely on unannounced M&A?